Posted by Michael Wonder on 03 Jan 2020
Additional evidence needed to assess histology-independent cancer drugs says paper co-authored by NICE staff
2 January 2020 - Paper looks at how histology-independent cancer drugs might be appraised.
Additional evidence collection will be needed to assess histology-independent cancer drugs - a new kind of cancer treatment - a paper published and co-authored by NICE staff has said.
The paper, published in the British Medical Journal, looks at how histology-independent cancer drugs might be appraised by organisations such as NICE.
